ArticleInternational journal of immunopathology and pharmacology
Apoptosis enhancement in MCF-7 cells: Synergistic effects of doxorubicin and the novel sulfonamide Zm-093.
Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer (BC) is a major global health issue. Combination therapies using chemical compounds have shown potential benefits, including reduced toxicity, slowed cancer cell growth, and improved treatment outcomes, compared to single-drug treatments.
objectivesThis study investigates the synergistic effects of doxorubicin (DOX) and Zm-093, a novel sulfonamide derivative with unique properties that offer potential advantages over existing sulfonamide compounds, including enhanced solubility and improved bioavailability, on apoptosis induction in BC cell lines.
methodsZm-093 was synthesized, and its structure was confirmed through Fourier-transform infrared spectroscopy (FT-IR) and nuclear magnetic resonance (NMR) spectroscopy. Cell viability was assessed using the MTT assay, while the combination index (CI) was calculated with Compusyn software to evaluate the synergistic interaction between DOX and Zm-093 in MCF-7 cells. The apoptotic effects of these compounds were further analyzed using western blotting, flow cytometry, and TUNEL assays.
resultsNotably, the combined treatment of DOX and Zm-093 at concentrations of 0.36 µM and 14.5 µM resulted in a 57% reduction in Bcl-2 expression compared to the control group. In contrast, expressions of pro-apoptotic proteins Bax and tBid, as well as caspase-3, increased significantly by 2.4, 3.3, and 5.7 times, respectively. Flow cytometry and TUNEL assay results indicated that the combination therapy significantly enhanced early apoptosis while minimizing necrosis.
conclusionThese findings confirm that DOX and Zm-093 exhibit synergistic effects on apoptotic pathways in MCF-7 cells, highlighting the potential of Zm-093 as a novel therapeutic agent with improved efficacy and reduced toxicity compared to existing sulfonamide compounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.